Drugs / EGFR806-specific chimeric antigen receptor (CAR) T cell
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03638167 | Mar 2019 → Dec 2023 | atypical teratoid rhabdoid tumor, childhood choroid plexus carcinoma, childhood medulloblastoma, ependymoma +3 | Seattle Children's Hospital | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EGFR806-specific chimeric antigen receptor (CAR) T cell | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03638167 ↗ |
| Modality | Cell therapy | “chimeric antigen receptor (CAR) T cell” NCT03638167 ↗ |
| Route | Other | “given via indwelling central nervous system (CNS) catheter” NCT03638167 ↗ |
| Target | EGFR | “EGFR806 specific chimeric antigen receptor (CAR)” NCT03638167 ↗ |